Decreased CYP2C19 abundance is especially relevant to the NAFLD patient population due to their cardiovascular comorbidities and therefore the increased importance of antiplatelet therapy. The gene discussed is CYP2C19; the disease is metabolic dysfunction-associated steatotic liver disease.